Ascendia

  MARKET NEWS

Absci & Caltech Join Forces to Accelerate Affordable HIV Therapeutic Vaccine Development
GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients With Chronic Lymphocytic Leukemia
Jnana Therapeutics Announces Dosing of First Participant in Phase 1b Clinical Trial in Individuals With PKU
CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora in Acute Pancreatitis
Lisata Therapeutics Announces US FDA Orphan Drug Designation Granted for the Treatment of Malignant Glioma
Comera Life Sciences Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore Platform

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Founded in 1946, Wirthwein Medical GmbH & Co. KG is today a high-performance system supplier in plastics processing and a development partner for plastic-based and customer-specific product solutions. Focusing on quality and innovation, Wirthwein Medical has also internationally made its mark in the diagnostics, medical technology, pharmaceutics industries – with high-precision, components, packaging, and systems. In addition, proprietary products in the pharmaceutical sector complement the product portfolio. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Clinigen Divests Global Rights to Four Cancer Support Therapies to CNX Therapeutics

Clinigen Divests Global Rights to Four Cancer Support Therapies to CNX Therapeutics

Clinigen Limited has completed the divestment of four cancer supportive care products from its established brands portfolio to CNX Therapeutics, a speciality pharmaceutical company with a focus on….

Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer & Expanded Pfizer Relationship

Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer & Expanded Pfizer Relationship

Cardiff Oncology, Inc. recently announced plans to advance the company’s lead program to the first-line setting of metastatic colorectal cancer (mCRC) and conduct its new CRDF-004 trial with study execution support from Pfizer….

Recursion Bridges the Protein & Chemical Space With Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds

Recursion Bridges the Protein & Chemical Space With Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds

Recursion recently announced it has successfully screened the Enamine REAL Space chemical library using its MatchMaker technology, recently acquired from Cyclica, to predict the protein target(s) for….

Silo Pharma Reaches Positive Milestone With Nasal Formulation for Anxiety, PTSD & Stress-Related Disorders

Silo Pharma Reaches Positive Milestone With Nasal Formulation for Anxiety, PTSD & Stress-Related Disorders

Silo Pharma, Inc. recently announced it has advanced the formulation development for its therapeutic drug, SPC-15. The liquid nasal formulation will be used in….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Addressing Regulatory Challenges for Ophthalmic Combination Products

WHITEPAPER - Addressing Regulatory Challenges for Ophthalmic Combination Products

By: Jeffrey Tremain and Ania VanDyke, AbbVie Contract Manufacturing

Regulatory authorities now consider ophthalmic formulations designed for administration as eye drops to be drug-device combination products.The regulatory compliance requirements for such combination products are much more complex than those for

…

WHITEPAPER - Use of a Platform Formulation Technology to De-Risk Solid-State Variation in Drug Development

WHITEPAPER - Use of a Platform Formulation Technology to De-Risk Solid-State Variation in Drug Development

Active pharmaceutical ingredients (APIs) can exist in multiple crystal forms, known as polymorphs, that are chemically identical. Polymorphs of an API can appear over the course of development and lead to deviations across batches affecting stability, tableting properties, flowability, solubility, …

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …

WHITEPAPER -  Long-Acting Injectable Nanoparticle Formulations

WHITEPAPER - Long-Acting Injectable Nanoparticle Formulations

Long acting injectable (LAI) formulations have been the subject of continued interest in the recent past due, in part, to their longer systemic circulation requiring less frequent dosing of drugs. Less frequent administration, as illustrated in Figure 1, make LAIs …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 23 – Excipients
August 30 – Gene Therapy